Der Kaninchen Polyklonal anti-PRKG2 Antikörper (ABIN360423) detektiert spezifisch PRKG2 in WB, IHC (p) und EIA.
Dieser Antikörper reagiert spezifisch mit Proben aus Human.
PRKG2
Reaktivität: Human
ELISA, IHC
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
ELISA: 1/1,000. Immunohistochemistry: 1/50 - 1/100. Western Blot: 1/100 - 1/500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.25 mg/mL
Buffer
PBS with 0.09 % (W/V) sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Target
PRKG2
(Protein Kinase, CGMP-Dependent, Type II (PRKG2))
Andere Bezeichnung
CGK2
Hintergrund
CGKII is thought to play a key role in a diverse set of physiological pathway. cGKII may mediate intestinal secretion of water and electrolytes induced by the E. coli toxin STa and the intestinal peptide guanylin. Edentification of the pathway that mediates intestinal fluid secretion by E. coli STa has potential medical implications because STa causes traveler's diarrhea and about 50 % of infant mortality in developing countries. Transfection experiments in human cells disclose that cGKII phosphorylates SOX9 and attenuates SOX9 function by inhibiting its nuclear entry. Impaired differentiation of cultured KMI chondrocytes can be restored by silencing Sox9 by RNA interference. cGKII is postulated to be a molecular switch that couples the cessation of proliferation and the start of hypertrophic chondrocyte differentiation through attenuating SOX9 function.Synonyms: PRKG2, PRKGR2, Type II cGMP-dependent protein kinase, cGKII, cGMP-dependent protein kinase 2